Madam Chair, members of the committee, thank you for the opportunity to appear.
My name is Stéphanie Michaud. I'm the president and CEO of the Canadian immunotherapy network BioCanRx, a federally funded organization dedicated to accelerating the development of made-in-Canada cancer immunotherapies, including CAR-T therapies and other cell therapies, from the laboratory to patients.
We appear before this committee as direct participants in the federal science funding system, not as observers of it.
I want to begin simply. This study matters. It is timely and we thank you. The questions you are asking about governance, accountability and transparency of federal science funding are not procedural questions. They have direct consequences for patients, including those far from urban centres, and for Canada's ability to retain the economic value of its own publicly funded discoveries.
Since 2015, BioCanRx has invested $54.5 million in federal funds, leveraged $156 million in partner contributions, treated more than 400 patients, created eight spin-out companies and supported 15 made-in-Canada clinical trials. BioCanRx alone accounts for 47% of all Canadian-origin cancer immunotherapy clinical trials since our founding.
Yet, between 2002 and March 2026, only 3.4% of all cancer immunotherapy trials conducted in Canada were based on Canadian discoveries. Our progress is real, yet it reveals exactly how large the structural problem remains.
Here's the problem in concrete terms. Think of it like funding a contractor to build an architecturally sound house, but not funding the permits, the soil test or the safety inspections needed to break ground. The money for construction is ready, the builder is qualified, but the house cannot be built, because the preparatory work was never funded. That is exactly what happened with three of our projects in 2023 and 2024, when we no longer had funding.
CIHR funded these projects to conduct clinical trials, but did not fund the GMP, assay development and toxicology studies required to file the clinical trial application with Health Canada. This work is too applied for CIHR's mandate. It is too early and risky for private capital. The project sat idle for at least a year. There was no federal mechanism to apply to. This gap between CIHR fundable research and clinic-ready therapy is structural, not incidental. It is invisible to any single federal accountability framework, because no single framework has visibility across the full pipeline.
All three projects subsequently received BioCanRx funding specifically designed to meet Health Canada's requirements. One has since opened a clinical trial providing a novel CAR T-cell therapy for both pediatric and adult blood cancer patients, a therapy that had no path to the clinic before BioCanRx intervened.
In a moment when Canada must harness its scientific strengths for sovereignty and competitiveness, we cannot afford governance structures that leave funded science stranded on the bench.
This is not a uniquely BioCanRx observation. In December 2025, we commissioned the Institute on Governance to benchmark Canada against six international comparators. What was the finding? Canada's underperformance reflects a structural design gap, not a lack of policy effort. Our health and innovation portfolios are complementary, but operate without mandated synchronization. This is a risk governance deficit. The U.S., U.K. and Japan have each built dedicated national translational infrastructure to answer the question Canada currently cannot: Is our investment reaching patients?
The committee is examining whether an independent oversight function, modelled on the Auditor General, could strengthen federal science accountability. We support that direction with one essential condition. The mandate must cover real-world outcomes, patient access, clinical deployment, manufacturing capacity and health system efficiency, not only publication counts and grant compliance.
It must evaluate coherence across the full pipeline, not just individual programs in isolation. The report also recommends a cross-departmental translational health research concierge program to guide innovators across the structural gaps between federal portfolios, a coordination mechanism that does not yet exist in Canada.
The ask is not more money. It is governance that is fit for purpose, transparent, independently evaluated and oriented towards real-world outcomes. Canada invests in science. This committee has the opportunity to ensure that we govern it wisely.
I look forward to your questions.
